In this article, we review the current use of and future direction for genetic testing and tumor profiling in patients with metastatic castration-resistant prostate cancer.
Bryden Considine, DO
Advertisement
Articles by Bryden Considine, DO
Here, we review the current use and future direction of novel therapeutic targets in the treatment of castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Evolving Perioperative Treatment Landscape for Resectable Gastric and Gastroesophageal Junction Cancers: A Q&A with Dr Nataliya Uboha
5